These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 17619742)
1. Best approach for low-risk superficial bladder cancer. Solsona E ScientificWorldJournal; 2006 Oct; 6():2638-45. PubMed ID: 17619742 [TBL] [Abstract][Full Text] [Related]
2. Optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer. van der Meijden AP ScientificWorldJournal; 2006 Mar; 6():2611-6. PubMed ID: 17619738 [TBL] [Abstract][Full Text] [Related]
3. The role of the surgeon and transurethral resection in the treatment of superficial bladder cancer. Nieder AM; Manoharan M ScientificWorldJournal; 2006 Jun; 6():2626-31. PubMed ID: 17619740 [TBL] [Abstract][Full Text] [Related]
4. Active surveillance for low-risk bladder cancer. Tiu A; Jenkins LC; Soloway MS Urol Oncol; 2014 Jan; 32(1):33.e7-10. PubMed ID: 23518309 [TBL] [Abstract][Full Text] [Related]
6. Optimizing outcomes at every stage of bladder cancer: do we practice it? Herr H; Konety B; Stein J; Sternberg CN; Wood DP Urol Oncol; 2009; 27(1):72-4. PubMed ID: 19111802 [TBL] [Abstract][Full Text] [Related]
7. Guidelines on diagnosis and treatment of superficial bladder cancer. Oosterlinck W Minerva Urol Nefrol; 2004 Mar; 56(1):65-72. PubMed ID: 15195031 [TBL] [Abstract][Full Text] [Related]
8. [EORTC risk tables--a new diagnostic tool in urology]. Bobiński J; Lipiński M Pol Merkur Lekarski; 2009 Dec; 27(162):524-8. PubMed ID: 20120722 [TBL] [Abstract][Full Text] [Related]
9. Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy? Volpe A; Racioppi M; Bongiovanni L; D'Agostino D; Totaro A; D'Addessi A; Marangi F; Palermo G; Pinto F; Sacco E; Bassi PF Urol Int; 2012; 89(3):311-8. PubMed ID: 22965159 [TBL] [Abstract][Full Text] [Related]
10. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how? Kurth KH Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):30-5. PubMed ID: 8727808 [TBL] [Abstract][Full Text] [Related]
11. New approaches in the treatment of metastatic transitional-cell cancer of the bladder. Corral DA; Logothetis CJ World J Urol; 1997; 15(2):139-43. PubMed ID: 9144905 [TBL] [Abstract][Full Text] [Related]
12. [S3 guideline for bladder cancer : Claim and reality - a critical commentary from the guideline coordinators]. Retz M; Maisch P; Gschwend JE Urologe A; 2016 Sep; 55(9):1188-91. PubMed ID: 27581238 [No Abstract] [Full Text] [Related]
13. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Kurth KH; Bouffioux C; Sylvester R; van der Meijden AP; Oosterlinck W; Brausi M Eur Urol; 2000; 37 Suppl 3():1-9. PubMed ID: 10828681 [TBL] [Abstract][Full Text] [Related]
14. [Aspects of bladder cancer]. Jocham D; Stöckle M; Sommerauer M Urologe A; 2012 Jun; 51(6):783. PubMed ID: 22674507 [No Abstract] [Full Text] [Related]
16. [Management of Ta, T1, and in situ bladder carcinoma: what is new?]. Irani J Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634 [TBL] [Abstract][Full Text] [Related]
17. New strategies in the treatment of Ta-T1 transitional cell carcinoma (TCC) of the bladder. Brausi MA ScientificWorldJournal; 2006 Oct; 6():2632-7. PubMed ID: 17619741 [TBL] [Abstract][Full Text] [Related]